A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)
Thoracic Surgery Oncology Group (TSOG) Protocol: Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)
1 other identifier
observational
338
2 countries
32
Brief Summary
The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
Longer than P75 for all trials
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 9, 2019
CompletedStudy Start
First participant enrolled
January 9, 2019
CompletedFirst Posted
Study publicly available on registry
January 14, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2027
February 18, 2026
February 1, 2026
8 years
January 9, 2019
February 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
lung cancer-specific survival
5 years
Eligibility Criteria
Patients with GGOs or mixed subsolid pulmonary nodules may be recruited from participating Thoracic Oncology Surgical Group (TSOG) sites, in accordance with local institutional practice and referral patterns, and assessed for eligibility based on the criteria listed below.
You may qualify if:
- Age greater than 18 years
- Have two or more GGOs on initial CT imaging
- GGOs must be measure ≤3.0 cm and ≥0.6 cm in the greatest dimension
- GGOs must be greater than half ground glass
You may not qualify if:
- Patients who are actively undergoing lung cancer treatment or have a history of lung cancer, except for cases of completely resected pathologic stage IA nonsmall cell lung cancer (NSCLC). Patients with stage IA NSCLC and multiple GGOs can enroll in this active surveillance protocol after complete resection of the NSCLC and confirmation of stage on final pathologic assessment.
- The presence of any solid lesion ≥0.6 cm suspicious for malignancy.
- Patients who are actively undergoing treatment for other malignancies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Memorial Sloan Kettering Cancer Centerlead
- M.D. Anderson Cancer Centercollaborator
- Brigham and Women's Hospitalcollaborator
- Duke Universitycollaborator
- Mayo Cliniccollaborator
- Université de Montréalcollaborator
- University of Pittsburghcollaborator
- University of Torontocollaborator
- Washington University School of Medicinecollaborator
Study Sites (32)
University of California San Diego
San Diego, California, 92103, United States
Stanford University Medical Center (Data collection only)
Stanford, California, 94305-5408, United States
Hartford Healthcare
Hartford, Connecticut, 06102, United States
Rush University Medical Center (Data collection only)
Chicago, Illinois, 606012, United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
George Washington University School of Medicine
St Louis, Missouri, 63110, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
Roswell Park Cancer Institute (Data Collection Only)
Buffalo, New York, 14263-0001, United States
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
New York Presbyterian Hospital
New York, New York, 10065, United States
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
Duke University Medical Center
Durham, North Carolina, 27701, United States
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103, United States
University of Pennsylvania (Data Collection Only)
Philadelphia, Pennsylvania, 19104, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
Temple University
Philadelphia, Pennsylvania, 19140, United States
Allegheny Health Network
Pittsburgh, Pennsylvania, 15212, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
Baylor University Medical Center
Houston, Texas, 77030, United States
McMaster University (Data Collection Only)
Hamilton, Ontario, L8N 3Z5, Canada
University Health Network
Toronto, Ontario, M5G 2C4, Canada
Centre Hospitalier de l'Université de Montreal
Montreal, Quebec, H2L 4M1, Canada
Related Publications (1)
Huang J, Tan KS, Altorki N, Antonoff M, Blackmon S, Bueno R, Burt B, Demmy T, Evans N, Donahoe L, Harpole D, Jarrar D, Kozower B, Lanuti M, Liberman M, Lin J, Liou D, Liptay M, Luketich J, Pennathur A, Petersen G, Ripley R, Rochefort M, Seder CW, Shrager J, Su S, Tong B, Shargall Y, Vaporciyan A, Waddell T, Weksler B, Wigle D, Yendamuri S, Jones DR. Initial patient characteristics of Thoracic Surgical Oncology Group 102: A multicenter prospective registry of active surveillance in patients with multiple ground-glass opacities. J Thorac Cardiovasc Surg. 2025 Apr;169(4):1100-1107. doi: 10.1016/j.jtcvs.2024.09.054. Epub 2024 Oct 10.
PMID: 39395785DERIVED
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
James Huang, MD
Memorial Sloan Kettering Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 9, 2019
First Posted
January 14, 2019
Study Start
January 9, 2019
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2027
Last Updated
February 18, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- SAP, ICF
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.